Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1993-8-19
|
pubmed:abstractText |
The present study was designed to characterize the antinociception produced by the administration of a potent muscarinic agonist into the intrathecal space of the lumbar spinal cord of male Sprague-Dawley rats. Seven days after surgical implantation of intrathecal catheters, animals were injected with graded doses of (+)-cis-methyldioxolane. (+)-cis-Methyldioxolane produced hot-plate and tail-flick antinociception for up to 90 min, peaking 5 to 30 min after injection. The dose of (+)-cis-methyldioxolane that inhibited nociception by 50% was 12 nmol in both the hot-plate and tail-flick tests. This antinociception was not accompanied by a general depression of other spontaneous motor responses. The tissue concentration of (+)-cis-methyl-dioxolane in the lumbar spinal cord present at the time of maximal hot-plate and tail-flick antinociception was approximately 12 microM. In similarity to (+)-cis-methyldioxolane, intrathecally administered (+)-muscarine also produced strong hot-plate and tail-flick antinociceptive responses. In contrast, intrathecally administered N-methylcarbachol, a nicotinic agonist, had no effect on nociception. Five-minute pretreatment with graded doses of pirenzepine, methoctramine, idazoxan, LY53857, or S-(-)-zacopride each significantly antagonized hot-plate and tail-flick antinociception produced by 37.5 nmol of (+)-cis-methyldioxolane in a dose-related manner with median effective antagonist doses in the range of 0.4 to 2.2 nmol. Intrathecal pretreatment with graded doses of prazosin or naloxone enhanced the antinociception produced by (+)-cis-methyldioxolane in the tail-flick but not the hot-plate tests. Intrathecal vehicle, S(-)-propranolol or mecamylamine did not alter (+)-cis-methyldioxolane-induced antinociception. The data suggest that the antinociceptive responses produced by intrathecally administered (+)-cis-methyldioxolane involve the stimulation of muscarinic M1 and/or M2 cholinergic receptors, and may also involve activation of alpha-2 adrenergic, 5-hydroxytryptamine1c/2 and 5-hydroxytryptamine3 serotonergic receptor systems at the level of the lumbar cord.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-methyldioxolane,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Carbachol,
http://linkedlifedata.com/resource/pubmed/chemical/Diamines,
http://linkedlifedata.com/resource/pubmed/chemical/Dioxolanes,
http://linkedlifedata.com/resource/pubmed/chemical/Mecamylamine,
http://linkedlifedata.com/resource/pubmed/chemical/Muscarine,
http://linkedlifedata.com/resource/pubmed/chemical/N-methylcarbamylcholine,
http://linkedlifedata.com/resource/pubmed/chemical/Parasympathomimetics,
http://linkedlifedata.com/resource/pubmed/chemical/Pirenzepine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Muscarinic,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/methoctramine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
266
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
329-38
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8101218-Adrenergic alpha-Antagonists,
pubmed-meshheading:8101218-Analgesia,
pubmed-meshheading:8101218-Animals,
pubmed-meshheading:8101218-Carbachol,
pubmed-meshheading:8101218-Diamines,
pubmed-meshheading:8101218-Dioxolanes,
pubmed-meshheading:8101218-Dose-Response Relationship, Drug,
pubmed-meshheading:8101218-Drug Interactions,
pubmed-meshheading:8101218-Injections, Spinal,
pubmed-meshheading:8101218-Male,
pubmed-meshheading:8101218-Mecamylamine,
pubmed-meshheading:8101218-Muscarine,
pubmed-meshheading:8101218-Nociceptors,
pubmed-meshheading:8101218-Pain Measurement,
pubmed-meshheading:8101218-Parasympathomimetics,
pubmed-meshheading:8101218-Pirenzepine,
pubmed-meshheading:8101218-Rats,
pubmed-meshheading:8101218-Rats, Sprague-Dawley,
pubmed-meshheading:8101218-Receptors, Adrenergic, alpha,
pubmed-meshheading:8101218-Receptors, Muscarinic,
pubmed-meshheading:8101218-Receptors, Opioid,
pubmed-meshheading:8101218-Receptors, Serotonin,
pubmed-meshheading:8101218-Spinal Cord,
pubmed-meshheading:8101218-Time Factors,
pubmed-meshheading:8101218-Tissue Distribution
|
pubmed:year |
1993
|
pubmed:articleTitle |
Characterization of the antinociception produced by intrathecally administered muscarinic agonists in rats.
|
pubmed:affiliation |
Department of Pharmacology, University of Kentucky College of Medicine, Lexington.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|